> It has been estimated that the average lifetime cost to the NHS for a person living with HIV is £360,000. Around two thirds (68%) of these costs were for anti-HIV drugs. The cost of a year’s HIV treatment is about £11,000 and of PrEP £5,000. The NHS obtains Truvada at a cost of £3,000–£4000 per person per year. People need to take HIV treatment for the rest of their lives but PrEP will generally be needed for a much shorter period. It is believed that the patent for one of the key drugs in Truvada, Tenofovir, expires in 2017, slashing the cost of the drug from this time. There has been a collective call on Gilead, from those involved in PrEP activism, to lower the price of Truvada for use in PrEP, as there are concerns that PrEP may not be deemed to be affordable.
> It has been estimated that the average lifetime cost to the NHS for a person living with HIV is £360,000. Around two thirds (68%) of these costs were for anti-HIV drugs. The cost of a year’s HIV treatment is about £11,000 and of PrEP £5,000. The NHS obtains Truvada at a cost of £3,000–£4000 per person per year. People need to take HIV treatment for the rest of their lives but PrEP will generally be needed for a much shorter period. It is believed that the patent for one of the key drugs in Truvada, Tenofovir, expires in 2017, slashing the cost of the drug from this time. There has been a collective call on Gilead, from those involved in PrEP activism, to lower the price of Truvada for use in PrEP, as there are concerns that PrEP may not be deemed to be affordable.